4QP1
Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4QP1 の概要
エントリーDOI | 10.2210/pdb4qp1/pdb |
関連するPDBエントリー | 4QP2 4QP3 4QP4 4QP6 4QP7 4QP8 4QP9 4QPA |
分子名称 | Mitogen-activated protein kinase 1, N-BENZYL-9H-PURIN-6-AMINE, IMIDAZOLE, ... (4 entities in total) |
機能のキーワード | kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
由来する生物種 | Homo sapiens (human) |
細胞内の位置 | Cytoplasm, cytoskeleton, spindle : P28482 |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 85844.32 |
構造登録者 | |
主引用文献 | Burdick, D.J.,Wang, S.,Heise, C.,Pan, B.,Drummond, J.,Yin, J.,Goeser, L.,Magnuson, S.,Blaney, J.,Moffat, J.,Wang, W.,Chen, H. Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors. Bioorg.Med.Chem.Lett., 25:4728-4732, 2015 Cited by PubMed Abstract: A fragment-based lead discovery approach was used to discover novel ERK2 inhibitors. The crystal structure of N-benzyl-9H-purin-6-amine 1 in complex with ERK2 elucidated its hinge-binding mode. In addition, the simultaneous binding of an imidazole molecule adjacent to 1 suggested a direction for fragment expansion. Structure-based core hopping applied to 1 led to 5H-pyrrolo[3,2-b]pyrazine (3) that afforded direct vectors to probe the pockets of interest while retaining the essential hinge binding elements. Utilizing the new vectors for SAR exploration, the new core 3 was quickly optimized to compound 39 resulting in a greater than 6600-fold improvement in potency. PubMed: 26338362DOI: 10.1016/j.bmcl.2015.08.048 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.7 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード